Oncolytic poliovirus for human tumors

US10799543B2 · kind B2 · utility

Assignee

• Duke University · US

Inventors

• Matthias Gromeier · Durham, US
• John H. Sampson · Durham, US
• Darell Bigner · Mebane, US
• Annick Desjardins · Durham, US
• Henry S. Friedman · Indianapolis, US

Key dates

• Filing date: Jul 9, 2019
• Grant date: Oct 13, 2020
• Expiry date: Jul 9, 2039

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.